Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced plans to release its financial results for Q4 and full-year 2020 on February 25, 2021, prior to market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced plans to release its financial results for Q4 and full-year 2020 on February 25, 2021, prior to market opening. A conference call is scheduled at 9:00 a.m. ET the same day to discuss these results and business highlights. Investors can access the call by phone or via the company’s website. A replay will be available shortly after the call until March 3, 2021. The firm is dedicated to improving the lives of individuals with kidney disease and was founded in 2007, headquartered in Cambridge, Massachusetts.
Positive
- Scheduled financial results release for Q4 and full-year 2020 on February 25, 2021.
- Conference call planned to discuss results and business highlights.
Negative
- None.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was +12.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 8, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2020 ended December 31, 2020, on Thursday, February 25, 2021, before the opening of the financial markets.
Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, February 25, 2021 to discuss its fourth quarter and full-year 2020 financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 5455117. The call will also be webcast live and can be accessed via the Investors section of the Company's website at http://ir.akebia.com.
A replay of the conference call will be available two hours after the completion of the call through March 3, 2021. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 5455117. An online archive of the conference call can be accessed via the Investors section of the Company's website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Investor Contact
Kristen K. Sheppard, Esq
ir@akebia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-and-discuss-recent-business-highlights-301223576.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.